Jennifer Moses Net Worth

The estimated Net Worth of Jennifer K. Moses is at least $1.85 Million dollars as of 3 January 2023. Ms. Moses owns over 2,368 units of G1 Therapeutics Inc stock worth over $412,257 and over the last 7 years she sold GTHX stock worth over $28,403. In addition, she makes $1,414,200 as Chief Financial Officer at G1 Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Moses GTHX stock SEC Form 4 insiders trading

Jennifer has made over 20 trades of the G1 Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 2,368 units of GTHX stock worth $13,071 on 3 January 2023.

The largest trade she's ever made was exercising 3,000 units of G1 Therapeutics Inc stock on 3 March 2021 worth over $11,160. On average, Jennifer trades about 1,166 units every 73 days since 2018. As of 3 January 2023 she still owns at least 57,820 units of G1 Therapeutics Inc stock.

You can see the complete history of Ms. Moses stock trades at the bottom of the page.

Jennifer Moses biography

Jennifer K. Moses CPA serves as Chief Financial Officer of the Company. Ms. Moses has served as our Vice President of Finance and Accounting from March 2015 to May 2019. Prior to joining us, Ms. Moses was a partner at Rankin McKenzie, LLC, from October 2007 to February 2015, where she served as acting chief financial officer and controller for venture-backed companies. In addition to preparing clients for growth by developing long-term financial plans and implementing financial systems, reporting and analysis, she led multiple clients through private placement offerings and acquisitions. Before joining Rankin McKenzie, Ms. Moses held roles of increasing responsibility at Deloitte, including providing tax services to clients and later focusing on strategic planning and internal communications in the Office of the CEO of Deloitte Tax. Ms. Moses earned her B.S. in Accounting from The Pennsylvania State University and is a certified public accountant in the State of North Carolina.

What is the salary of Jennifer Moses?

As the Chief Financial Officer of G1 Therapeutics Inc, the total compensation of Jennifer Moses at G1 Therapeutics Inc is $1,414,200. There are 5 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.

How old is Jennifer Moses?

Jennifer Moses is 44, she's been the Chief Financial Officer of G1 Therapeutics Inc since 2019. There are 25 older and no younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.

What's Jennifer Moses's mailing address?

Jennifer's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.

Insiders trading at G1 Therapeutics Inc

Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.

What does G1 Therapeutics Inc do?

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.

Complete history of Ms. Moses stock trades at G1 Therapeutics Inc

G1 Therapeutics Inc executives and stock owners

G1 Therapeutics Inc executives and other stock owners filed with the SEC include:

• Mark Avagliano,
  Chief Business Officer
• James Hanson,
  General Counsel, Secretary
• Mark Velleca,
  President, Chief Executive Officer, Director
• Terry Murdock,
  Chief Operating Officer
• Garry Nicholson,
  Independent Chairman of the Board
• Jennifer Moses,
  Chief Financial Officer
• Rajesh Malik,
  Chief Medical Officer, Senior Vice President - Research and Development
• Dr. Mark A. Velleca M.D., Ph.D.,
  Sr. Advisor & Director
• Mark Avagliano,
  Chief Bus. Officer
• Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
  Chief Medical Officer and Sr. VP of R&D
• Dr. Rajesh K. Malik,
  Chief Medical Officer and Sr. VP of R&D
• Andrew Perry,
  Chief Commercial Officer
• Jennifer K. Moses CPA,
  Chief Financial Officer
• Jennifer K. Moses,
  Chief Financial Officer
• Seth Rudnick,
  Independent Director
• Glenn Muir,
  Independent Director
• Cynthia Schwalm,
  Independent Director
• Fredric Eshelman,
  Independent Director
• Willie Deese,
  Independent Director
• Andrew Witty,
  Independent Director
• John Bailey,
  Independent Director
• Soma Gupta,
  Chief Commercial Officer
• Jay Strum,
  Chief Scientific Officer
• Terry L. Murdock,
  Chief Operating Officer
• Blake Jensen,
  VP of Quality & Compliance
• William C. Roberts,
  VP of Investor Relations & Corp. Communications
• Dr. Jay C. Strum,
  Chief Scientific Officer
• Alexander D. Smith M.S.,
  VP of Technical Operations
• John E. Bailey Jr.,
  CEO, Pres & Director
• Clay Hatteras Venture Advis...,
  
• Capital Management, L.P.Ra ...,
  
• Christy L Shaffer,
  Director
• Ventures, Inc. Med Immune,
  10% owner
• Ventures, Llc Eshelman,
  10% owner
• Clay Hatteras Venture Advis...,
  
• Barclay A Phillips,
  SVP & Chief Financial Officer
• Monica R. Thomas,
  Chief Legal & People Officer
• Jacks Lee,
  
• John Demaree,
  Chief Commercial Officer
• Alicia Secor,
  
• Cynthia Louise Flowers,
  
• Andrew Perry,
  Chief Commercial Officer
• Norman Sharpless,
  
• John W. V Umstead,
  Chief Financial Officer